{"id":769403,"date":"2023-07-12T16:21:23","date_gmt":"2023-07-12T20:21:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/"},"modified":"2023-07-12T16:21:23","modified_gmt":"2023-07-12T20:21:23","slug":"bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/","title":{"rendered":"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Bicycle Therapeutics Announces Proposed $200 Million Public Offering <\/b><b>of American Depositary Shares and Non-Voting Ordinary Shares<\/b><\/p>\n<p>CAMBRIDGE, England &amp; BOSTON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nBicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (<i>Bicycle<sup>\u00ae<\/sup><\/i>) technology, today announced that it has commenced an underwritten public offering of $200 million of American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares. All of the ADSs and non-voting ordinary shares in the proposed offering will be sold by Bicycle. In connection with the offering, Bicycle intends to grant the underwriters in the offering a 30-day option to purchase up to an additional $30 million of ADSs. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.<\/p>\n<p>\nBicycle plans to use the net proceeds from the offering to fund the continued development of its proprietary pipeline and for other research and development, as well as for general corporate purposes.<\/p>\n<p>\nGoldman Sachs &amp; Co. LLC, Jefferies and Leerink Partners are acting as joint book-running managers for the proposed offering.<\/p>\n<p>\nThe proposed offering is being made pursuant to a \u201cshelf\u201d registration statement on Form S-3ASR that was filed by Bicycle with the Securities and Exchange Commission (\u201cSEC\u201d) and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=53451830&amp;newsitemid=20230712446032&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=1&amp;md5=b89787e7aed537f833c3399e72bff386\">www.sec.gov<\/a>. Copies of the preliminary prospectus supplement, final prospectus supplement and accompanying prospectus, when available, may be obtained from: Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or by email at <a rel=\"nofollow\" href=\"mailto:prospectus-ny@ny.email.gs.com\">prospectus-ny@ny.email.gs.com<\/a>; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by email at <a rel=\"nofollow\" href=\"mailto:Prospectus_Department@Jefferies.com\">Prospectus_Department@Jefferies.com<\/a>; or SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at <a rel=\"nofollow\" href=\"mailto:syndicate@leerink.com\">syndicate@leerink.com<\/a>.<\/p>\n<p>\nThis press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward\u2010looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Certain statements contained in this press release, including those relating to the timing and completion of the offering, the anticipated total gross proceeds from the offering and the planned use of proceeds of the offering are forward\u2010looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward\u2010looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed offering, the completion of the offering on the anticipated terms or at all, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed offering and general economic conditions. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Bicycle\u2019s filings with the SEC, including under the heading \u201cRisk Factors\u201d contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering to be filed with the SEC, which are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=53451830&amp;newsitemid=20230712446032&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=b76d94ae0d1d53ef8e8263587cd77bfd\">www.sec.gov<\/a>. The forward\u2010looking statements in this press release speak only as of the date of this document. Except as required by law, Bicycle assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Bicycle\u2019s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230712446032\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230712446032\/en\/<\/a><\/span><\/p>\n<p>\nDavid Borah, CFA<br \/>\n<br \/>SVP, Capital Markets &amp; Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:david.borah@bicycletx.com\">david.borah@bicycletx.com<br \/>\n<\/a><br \/>617-203-8300<\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts Europe United States United Kingdom North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Diabetes Clinical Trials Pharmaceutical Cardiology Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230712446032\/en\/1840143\/3\/BCYC_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares CAMBRIDGE, England &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211; Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that it has commenced an underwritten public offering of $200 million of American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares. All of the ADSs and non-voting ordinary shares in the proposed offering will be sold by Bicycle. In connection with the offering, Bicycle intends to grant the underwriters in the offering a 30-day option to purchase up to an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-769403","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares CAMBRIDGE, England &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211; Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that it has commenced an underwritten public offering of $200 million of American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares. All of the ADSs and non-voting ordinary shares in the proposed offering will be sold by Bicycle. In connection with the offering, Bicycle intends to grant the underwriters in the offering a 30-day option to purchase up to an &hellip; Continue reading &quot;Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-12T20:21:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares\",\"datePublished\":\"2023-07-12T20:21:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/\"},\"wordCount\":804,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/\",\"name\":\"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-07-12T20:21:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/","og_locale":"en_US","og_type":"article","og_title":"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares - Market Newsdesk","og_description":"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares CAMBRIDGE, England &amp; BOSTON&#8211;(BUSINESS WIRE)&#8211; Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that it has commenced an underwritten public offering of $200 million of American Depositary Shares (\u201cADSs\u201d), each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares. All of the ADSs and non-voting ordinary shares in the proposed offering will be sold by Bicycle. In connection with the offering, Bicycle intends to grant the underwriters in the offering a 30-day option to purchase up to an &hellip; Continue reading \"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-12T20:21:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares","datePublished":"2023-07-12T20:21:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/"},"wordCount":804,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/","name":"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-07-12T20:21:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230712446032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-proposed-200-million-public-offering-of-american-depositary-shares-and-non-voting-ordinary-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/769403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=769403"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/769403\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=769403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=769403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=769403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}